Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)
Scope of the Report
The report titled “Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)” provides an in-depth analysis of global knee osteoarthritis market with special focus on non conservative treatment for OA such as Viscosupplementation. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2016-20). Further, key drug manufacturers of the global knee osteoarthritis market like Johnson & Johnson, Zimmer Biomet Holdings and Stryker Roche are profiled in the report.
Segment Coverage
Osteoarthritis is the most prevalent joint disease mainly affecting middle-age to elderly population globally. It can occur in any joint such as knees, hips, hands and spine; knee being one of the most affected joints. Knee osteoarthritis is a progressive, degenerative disorder involving the degradation of the intra-articular cartilage, joint lining, ligaments, and the underlying bone of the knee. There are many factors that can increase the risk of osteoarthritis in a person such as age, being overweight, genetic condition, etc. Sometimes a combination of these factors leads to such condition.
Treatments for knee OA are based on the stage of disease. Depending on the severity of OA, there are different approaches and treatments available that helps the patient with lessening the pain and increasing mobility. Conservative approach is used for treatment in initial stages of OA. With increase in severity Cortisone injections and Viscosupplementation are used.
Global knee osteoarthritis market is driven by increase in geriatric population, high rate of obesity, rising healthcare expenditure and high incidence of knee OA in the US market. Factors which are affecting the industry includes decline in reimbursement and coverage, defective medical devices, lack of trained healthcare workers and regulatory risk. The market is characterized by growth in Outsourced Precision Manufacturing segment and advent of HA single injection from non-animal source.
The report titled “Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)” provides an in-depth analysis of global knee osteoarthritis market with special focus on non conservative treatment for OA such as Viscosupplementation. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2016-20). Further, key drug manufacturers of the global knee osteoarthritis market like Johnson & Johnson, Zimmer Biomet Holdings and Stryker Roche are profiled in the report.
Segment Coverage
- Viscosupplementation Market
- Single-Injection & Multi-Injection Market
- Gx Steroids Market
- The US
- Johnson & Johnson-DePuy
- Zimmer Biomet Holdings, Inc.
- Stryker Corporation
Osteoarthritis is the most prevalent joint disease mainly affecting middle-age to elderly population globally. It can occur in any joint such as knees, hips, hands and spine; knee being one of the most affected joints. Knee osteoarthritis is a progressive, degenerative disorder involving the degradation of the intra-articular cartilage, joint lining, ligaments, and the underlying bone of the knee. There are many factors that can increase the risk of osteoarthritis in a person such as age, being overweight, genetic condition, etc. Sometimes a combination of these factors leads to such condition.
Treatments for knee OA are based on the stage of disease. Depending on the severity of OA, there are different approaches and treatments available that helps the patient with lessening the pain and increasing mobility. Conservative approach is used for treatment in initial stages of OA. With increase in severity Cortisone injections and Viscosupplementation are used.
Global knee osteoarthritis market is driven by increase in geriatric population, high rate of obesity, rising healthcare expenditure and high incidence of knee OA in the US market. Factors which are affecting the industry includes decline in reimbursement and coverage, defective medical devices, lack of trained healthcare workers and regulatory risk. The market is characterized by growth in Outsourced Precision Manufacturing segment and advent of HA single injection from non-animal source.
1. EXECUTIVE SUMMARY
2. BACKGROUND
3. KNEE OSTEOARTHRITIS
3.1 Signs & Symptoms
3.2 Causes
3.3 Treatment
4. GLOBAL KNEE OSTEOARTHRITIS MARKET ANALYSIS
4.1 Global Knee Osteoarthritis Market Size (Actual & Forecast)
4.2 Market Share by Geography
5. THE U.S. KNEE OSTEOARTHRITIS MARKET
5.1 The U.S. Knee Osteoarthritis Market Analysis
5.1.1 The U.S. Knee Market Size
5.2 The U.S. Knee Osteoarthritis Treatment Market
5.2.1 The U.S. Viscosupplementation Market Size by Value
5.2.2 The U.S. Viscosupplementation Market Size by Volume
5.2.3 The U.S. Viscosupplementation Market Share by Competitors
5.2.4 The U.S. Single-Injection & Multi-Injection Market
5.2.5 The U.S. Gx Steroids Market Size by Volume
5.2.6 The U.S. Gx Steroids Market Share by Competitors
6. GLOBAL KNEE OSTEOARTHRITIS MARKET TRENDS
6.1 Growth in Outsourced Precision Manufacturing Segments
6.2 HA Single Injection from Non-Animal Source
7. GLOBAL KNEE OSTEOARTHRITIS MARKET: GROWTH DRIVERS & CHALLENGES
7.1 Growth Drivers
7.1.1 Increasing Geriatric Population
7.1.2 High Rate of Obesity
7.1.3 Rising Healthcare Expenditure
7.1.4 High Incidence in the US
7.2 Challenges
7.2.1 Decline in Reimbursement and Coverage
7.2.2 Defective Medical Devices
7.2.3 Lack of Trained Healthcare Workers
7.2.4 Regulatory risk
8. COMPETITIVE LANDSCAPE
9. COMPANY PROFILE
9.1 Johnson & Johnson-DePuy
9.1.1 Business Overview
9.1.2Financial Overview
9.1.3 Business Strategies
9.2 Zimmer Biomet Holdings, Inc.
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategies
9.3 Stryker Corporation
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3Business Strategies
2. BACKGROUND
3. KNEE OSTEOARTHRITIS
3.1 Signs & Symptoms
3.2 Causes
3.3 Treatment
4. GLOBAL KNEE OSTEOARTHRITIS MARKET ANALYSIS
4.1 Global Knee Osteoarthritis Market Size (Actual & Forecast)
4.2 Market Share by Geography
5. THE U.S. KNEE OSTEOARTHRITIS MARKET
5.1 The U.S. Knee Osteoarthritis Market Analysis
5.1.1 The U.S. Knee Market Size
5.2 The U.S. Knee Osteoarthritis Treatment Market
5.2.1 The U.S. Viscosupplementation Market Size by Value
5.2.2 The U.S. Viscosupplementation Market Size by Volume
5.2.3 The U.S. Viscosupplementation Market Share by Competitors
5.2.4 The U.S. Single-Injection & Multi-Injection Market
5.2.5 The U.S. Gx Steroids Market Size by Volume
5.2.6 The U.S. Gx Steroids Market Share by Competitors
6. GLOBAL KNEE OSTEOARTHRITIS MARKET TRENDS
6.1 Growth in Outsourced Precision Manufacturing Segments
6.2 HA Single Injection from Non-Animal Source
7. GLOBAL KNEE OSTEOARTHRITIS MARKET: GROWTH DRIVERS & CHALLENGES
7.1 Growth Drivers
7.1.1 Increasing Geriatric Population
7.1.2 High Rate of Obesity
7.1.3 Rising Healthcare Expenditure
7.1.4 High Incidence in the US
7.2 Challenges
7.2.1 Decline in Reimbursement and Coverage
7.2.2 Defective Medical Devices
7.2.3 Lack of Trained Healthcare Workers
7.2.4 Regulatory risk
8. COMPETITIVE LANDSCAPE
9. COMPANY PROFILE
9.1 Johnson & Johnson-DePuy
9.1.1 Business Overview
9.1.2Financial Overview
9.1.3 Business Strategies
9.2 Zimmer Biomet Holdings, Inc.
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategies
9.3 Stryker Corporation
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3Business Strategies
LIST OF FIGURES AND TABLES
Figure 1: Normal Joint (Front View)
Figure 2: Knee Joint with Mild Osteoarthritis (Front View)
Figure 3: Risk Factors for Knee Osteoarthritis
Figure 4: Global Knee Osteoarthritis Market Size, 2013-20E (US$ Billions)
Figure 5: Global Knee Osteoarthritis Market Share by Geography (2014)
Figure 6: The U.S. Population 65 and Older (%), 2010-25E
Figure 7: Musculoskeletal Diagnoses for Individuals 65 or Older in the US (2015E)
Figure 8: % of Obese Americans over Time, 1988-2010
Figure 9: The U.S. Knee Market Size, 2010-14 (US$ Billions)
Figure 10: The U.S. Viscosupplementation Market Size by Value, 2010-15E (US$ Millions)
Figure 11: The U.S. Viscosupplementation Market Size Forecast, 2016E-20E (US$ Millions)
Figure 12: The U.S. Viscosupplementation Market Size by Volume, 2013-20E (#Treatment in Millions)
Figure 13: The U.S. HA Market Share by Competitors, 2013-2020E (%)
Table 1: The U.S. Viscosupplements Market Share by Companies (2014)
Figure 14: The U.S. Gx Steroids Market Size by Volume, 2013-20E (#Treatment in Millions)
Figure 15: The U.S. Gx Steroids Market Share by Competitors, 2013-2020E (%)
Figure 16: Growth in Outsourced Precision Manufacturing Segments, 2009-17E (US$ Millions)
Figure 17: Global Ageing (60+) Population, 2015-50E (Millions)
Figure 18: The Cycle of Obesity and Knee Osteoarthritis
Figure 19: Global Healthcare Expenditure, 2005-15E (US$ Trillions)
Table 2: Competing Pipeline Products in the Global Knee Osteoarthritis Market
Table 3: Multi-Injection & Single-Injection Products in the US Viscosupplements Market (2014)
Figure 20: Johnson & Johnson Revenue by Business Segment (2014)
Figure 21: Johnson & Johnson Consolidated Revenue, 2009-14 (US$ Billions)
Figure 22: Zimmer Biomet Holdings, Inc. Revenue by Business Segment (2014)
Figure 23: Zimmer Biomet Holdings, Inc. Revenue, 2009-14 (US$ Billions)
Figure 25: Stryker Revenue 2009 - 14 (US$ Billions)
Figure 1: Normal Joint (Front View)
Figure 2: Knee Joint with Mild Osteoarthritis (Front View)
Figure 3: Risk Factors for Knee Osteoarthritis
Figure 4: Global Knee Osteoarthritis Market Size, 2013-20E (US$ Billions)
Figure 5: Global Knee Osteoarthritis Market Share by Geography (2014)
Figure 6: The U.S. Population 65 and Older (%), 2010-25E
Figure 7: Musculoskeletal Diagnoses for Individuals 65 or Older in the US (2015E)
Figure 8: % of Obese Americans over Time, 1988-2010
Figure 9: The U.S. Knee Market Size, 2010-14 (US$ Billions)
Figure 10: The U.S. Viscosupplementation Market Size by Value, 2010-15E (US$ Millions)
Figure 11: The U.S. Viscosupplementation Market Size Forecast, 2016E-20E (US$ Millions)
Figure 12: The U.S. Viscosupplementation Market Size by Volume, 2013-20E (#Treatment in Millions)
Figure 13: The U.S. HA Market Share by Competitors, 2013-2020E (%)
Table 1: The U.S. Viscosupplements Market Share by Companies (2014)
Figure 14: The U.S. Gx Steroids Market Size by Volume, 2013-20E (#Treatment in Millions)
Figure 15: The U.S. Gx Steroids Market Share by Competitors, 2013-2020E (%)
Figure 16: Growth in Outsourced Precision Manufacturing Segments, 2009-17E (US$ Millions)
Figure 17: Global Ageing (60+) Population, 2015-50E (Millions)
Figure 18: The Cycle of Obesity and Knee Osteoarthritis
Figure 19: Global Healthcare Expenditure, 2005-15E (US$ Trillions)
Table 2: Competing Pipeline Products in the Global Knee Osteoarthritis Market
Table 3: Multi-Injection & Single-Injection Products in the US Viscosupplements Market (2014)
Figure 20: Johnson & Johnson Revenue by Business Segment (2014)
Figure 21: Johnson & Johnson Consolidated Revenue, 2009-14 (US$ Billions)
Figure 22: Zimmer Biomet Holdings, Inc. Revenue by Business Segment (2014)
Figure 23: Zimmer Biomet Holdings, Inc. Revenue, 2009-14 (US$ Billions)
Figure 25: Stryker Revenue 2009 - 14 (US$ Billions)
